{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:52:03Z","timestamp":1789213923802,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Crown-Princess Lovisa"},{"name":"Axel Tiellmans Minnesfond"},{"name":"Samariten, S\u00e4llskapet Barnav\u00e5rd and Promobilia"},{"name":"Norrbacka Eugenia, Promobilia, RBU"},{"name":"Sunnerdahls foundations"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.bone.2016.02.015","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T20:41:22Z","timestamp":1457210482000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate"],"prefix":"10.1016","volume":"87","author":[{"given":"K.","family":"Lindahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kindmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Malmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Grigelioniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"S\u00f6derh\u00e4ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6.","family":"Ljunggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"\u00c5str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2016.02.015_bb0005","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","article-title":"Genetic epidemiology, prevalence, and genotype\u2013phenotype correlations in the Swedish population with osteogenesis imperfecta","volume":"23","author":"Lindahl","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.bone.2016.02.015_bb0010","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","article-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta","volume":"355","author":"Barnes","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.02.015_bb0015","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/humu.20799","article-title":"CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta","volume":"29","author":"Baldridge","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2016.02.015_bb0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","article-title":"PPIB mutations cause severe osteogenesis imperfecta","volume":"85","author":"van Dijk","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2016.02.015_bb0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","article-title":"Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta","volume":"86","author":"Christiansen","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2016.02.015_bb0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ajhg.2010.02.022","article-title":"Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta","volume":"86","author":"Alanay","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2016.02.015_bb0035","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/jbmr.487","article-title":"Mutations in SERPINF1 cause osteogenesis imperfecta type VI","volume":"26","author":"Homan","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.02.015_bb0040","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jbmr.250","article-title":"Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome","volume":"26","author":"Kelley","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.02.015_bb0045","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/humu.22133","article-title":"Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome\u2013osteogenesis imperfecta phenotypic spectrum","volume":"33","author":"Puig-Hervas","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2016.02.015_bb0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","article-title":"A mutation in the 5\u2032-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus","volume":"91","author":"Semler","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2016.02.015_bb0055","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jmedgenet-2012-101142","article-title":"Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation","volume":"49","author":"Shaheen","year":"2012","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2016.02.015_bb0060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1215458","article-title":"WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta","volume":"368","author":"Laine","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.02.015_bb0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1750-1172-8-154","article-title":"Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans","volume":"8","author":"Symoens","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bone.2016.02.015_bb0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1308223","article-title":"PLS3 mutations in X-linked osteoporosis with fractures","author":"van Dijk","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.02.015_bb0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/nar\/26.1.253","article-title":"The human collagen mutation database 1998","volume":"26","author":"Dalgleish","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bone.2016.02.015_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/nar\/25.1.181","article-title":"The human type I collagen mutation database","volume":"25","author":"Dalgleish","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bone.2016.02.015_bb0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2016.02.015_bb0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/humu.20429","article-title":"Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans","volume":"28","author":"Marini","year":"2007","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2016.02.015_bb0095","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/ejhg.2009.242","article-title":"Genotype\u2013phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I","volume":"18","author":"Rauch","year":"2010","journal-title":"Eur. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.bone.2016.02.015_bb0100","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Phillipi","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2016.02.015_bb0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2008-1531","article-title":"Clinical review 1: bisphosphonate use in childhood osteoporosis","volume":"94","author":"Bachrach","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.02.015_bb0110","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","article-title":"Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment","volume":"39","author":"Land","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.02.015_bb0115","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 5","key":"10.1016\/j.bone.2016.02.015_bb0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000110463","article-title":"Treatment of osteogenesis imperfecta: who, why, what?","volume":"68","author":"Glorieux","year":"2007","journal-title":"Horm. Res."},{"key":"10.1016\/j.bone.2016.02.015_bb0125","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"7","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2016.02.015_bb0130","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Phillipi","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2016.02.015_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","author":"Palomo","year":"2015","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.02.015_bb0140","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/adc.2006.096552","article-title":"Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta","volume":"92","author":"Astrom","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2016.02.015_bb0145","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.02.015_bb0150","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2016.02.015_bb0155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","article-title":"Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta","volume":"87","author":"Astrom","year":"1998","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bone.2016.02.015_bb0160","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1651-2227.2010.01968.x","article-title":"Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta","volume":"99","author":"Astrom","year":"2010","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bone.2016.02.015_bb0165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1086\/301689","volume":"62","author":"Korkko","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2016.02.015_bb0170","unstructured":"Dalgleish, R. http:\/\/www.le.ac.uk\/ge\/collagen\/)."},{"key":"10.1016\/j.bone.2016.02.015_bb0175","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","article-title":"Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV","volume":"111","author":"Zeitlin","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.bone.2016.02.015_bb0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00297295","article-title":"Osteogenesis imperfecta: a clinical study of the first ten years of life","volume":"50","author":"Vetter","year":"1992","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.02.015_bb0185","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00256-013-1723-3","article-title":"Combining areal DXA bone mineral density and vertebrae postero-anterior width improves the prediction of vertebral strength","volume":"42","author":"Taton","year":"2013","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.bone.2016.02.015_bb0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bone.2008.11.006","article-title":"Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations","volume":"44","author":"Garnero","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.02.015_bb0195","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bone.2004.02.023","article-title":"Bone turnover markers in patients with osteogenesis imperfecta","volume":"34","author":"Braga","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.02.015_bb0200","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.02.015_bb0205","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.02.015_bb0210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.02.015_bb0215","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.02.015_bb0220","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/0140-6736(93)92935-M","article-title":"Mineralisation defects with pamidronate therapy for Paget's disease","volume":"342","author":"Adamson","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2016.02.015_bb0225","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.02.015_bb0230","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/17453671003628780","article-title":"Epidemiology of fractures in children and adolescents","volume":"81","author":"Hedstrom","year":"2010","journal-title":"Acta Orthop."},{"key":"10.1016\/j.bone.2016.02.015_bb0235","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11914-014-0227-y","article-title":"The epidemiology of fractures in otherwise healthy children","volume":"12","author":"Clark","year":"2014","journal-title":"Curr. Osteoporos. Rep."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216300412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216300412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T10:57:34Z","timestamp":1536922654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216300412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":47,"alternative-id":["S8756328216300412"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.02.015","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}